XML 38 R23.htm IDEA: XBRL DOCUMENT
v3.21.1

Shareholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2020
Stockholders' Equity Note [Abstract] |
SHAREHOLDERS' EQUITY | NOTE 16:- SHAREHOLDERS’ EQUITY
| a. | Ordinary Shares:
| 1. | Issuance of Ordinary Shares in connection with a Standby Equity Distribution Agreement:
On May 8, 2017 the Company entered into a Standby Equity Distribution Agreement (“SEDA”), with YA II PN Ltd. (“YA”), for the sale of up to $2,000 of its Ordinary Shares to YA during a four-year period beginning on March 1, 2018, the date on which the Securities and Exchange Commission first declares effective a registration statement registering the resale of the Company’s Ordinary Shares by YA. For each Ordinary Share purchased under the SEDA, YA will pay 93% of the lowest daily VWAP (as defined below) of the Ordinary Shares during the three consecutive trading days, following the date of an advance notice from the Company (provided such VWAP is greater than or equal to 90% of the last closing price of the Ordinary shares at the time of delivery of the advance notice). Notwithstanding the forgoing, the notice shall not exceed $500. “VWAP” is defined as of any date, to be such date’s daily dollar volume-weighted average price of the Ordinary Shares as reported by Bloomberg, LP. The Company may terminate the SEDA at any time upon prior notice to YA, as long as there are no advance notices outstanding and the Company has paid to YA all amounts then due. In connection with the SEDA, the Company issued 67,307 ordinary shares to YA as a commitment fee. The fair value of such shares was approximately $ 140 and was accounted for as prepaid expenses and amortized to equity by December 31, 2020, as the Company doesn’t anticipate to further utilize this equity line. During the year 2020, the Company issued to YA 41,090 Ordinary Shares, for a total amount of $100, net of amortization of the remaining balance of the commitment fee which amounted to $77. During the year 2019, the Company issued to YA 158,023 Ordinary Shares, for a total amount of $465, net of amortization of commitment fee in the amount of $ 35. During the year 2018, the Company issued to YA 197,025 Ordinary Shares, for a total amount of $377, net of amortization of commitment fee in the amount of $ 23. As of March 15, 2021, $1,000,000 has been drawn on this equity line for which the Company has issued an aggregate of 396,138 Ordinary Shares.
| 2. | Share-based compensation expense:
In the years 2018 and 2020, the Company issued to its directors and officers 248,000 options to purchase Ordinary Shares and recorded an expenses in amount of $210. The options’ exercise price is calculated as the weighted average of the closing prices of the shares on the Nasdaq Capital Market during the 20 trading days preceding the date of approval of the grant by the Board of Directors or, in case of grants to the Chief Executive Officer or Directors, 20 trading days preceding the approval of the grant by the shareholders. The options will vest and become exercisable annually over a period of three years, in three equal parts, such that one third of the options shall vest on each of the first, second and third anniversary of the grant date, provided that the officer or director is still holding its office at the applicable vesting date. The options shall expire on the fifth anniversary of the grant date. Payment of the exercise price must be made in full upon exercise of the options, by cash or check or cash equivalent, or by the assignment of the proceeds of a sale of some or all of the Ordinary Shares being acquired upon exercise of options, or by any combination of the foregoing. On February 25, 2019 and on March 31, 2020, the Company issued to its officers 20,858 Ordinary Shares (equivalent to $62) and 7,665 Ordinary shares (equivalent to $12), respectively, as a bonus, which was approved by the Board of Directors and shareholders.
| 3. | On May 16, 2019 the Company entered into and closed a securities purchase agreement with several investors for the sale of 400,000 Ordinary Shares at a price of $2.50 per share, resulting in gross proceeds of $1,000 and $65 issuance expenses. In addition, the Company issued to the investors 240,000 warrants with an exercise price of $3.30 per Ordinary Share. The warrants shall be exercisable for 3.5 years and shall be subject to a three-year vesting period as follows: one third of the warrants shall vest annually (upon the lapse of 12 months, 24 months and 36 months from issuance), provided that on the applicable vesting date the investor did not sell any of the Ordinary Shares purchased in the private placement. Vesting of all of the warrants shall be accelerated in the event that any one or more shareholders acting together acquire a block of 40% of the Company’s issued and outstanding share capital. In addition, the Company issued 60,000 warrants as fees to a placement agent.
| 4. | On February 19, 2020, the Company, through its wholly owned subsidiary, Ruby Tech Inc. entered into an agreement for a loan from YA II PN, LTD (“YA II”) in the principal amount of $600,000. The principal loan amount bears an interest rate of 8% per annum and is not secured and is guaranteed by BOS-Odem and by the company. The loan is paid in 12 monthly installments of principal and interest starting from March 2020. BOS issued to YA II warrants to purchase up to 100,000 Ordinary Shares of the Company at an exercise price of $3.00 per Ordinary Share. If at the time of exercise the shares underlying the warrants are not subject to an effective registration statement, the warrants may be exercised on a cashless basis. The warrants are exercisable for a period of two years from issuance. The Company recorded financial expenses in the amount of $30 that reflects the fair market value of the warrants. As of December 31, 2020 the entire balance of the loan was repaid.
| 5. | At the Annual General Meeting of shareholders held on July 18, 2018, it was approved to increase the Company’s authorized share capital by 2,000,000 Ordinary Shares, from 4,000,000 authorized shares to 6,000,000 authorized shares.
At the Annual General Meeting of shareholders held on December 16, 2020, it was approved to increase the Company’s authorized share capital by 2,000,000 Ordinary Shares, from 6,000,000 authorized shares to 8,000,000 authorized shares. In addition, it was approved to cancel the Company’s Ordinary Shares’ nominal value, so that following such cancellation, the authorized share capital of the Company will be comprised of 8,000,000 Ordinary Shares of no nominal value each, ranking pari passu in all respects.
| b. | Warrants to shareholders
The Company’s outstanding warrants to shareholders as of December 31, 2020 are as follows:
Outstanding and exercisable warrants |  |  | Weighted average exercise price of outstanding warrants |  |  | Weighted average Remaining contractual life (years) |
| 400,000 |  |  |  | 3.23 |  |  |  | 1.65 |
| c. | Stock option plans:
In May 2003 the Company’s shareholders approved the adoption of the 2003 Israeli Stock Option Plan or the Plan. In December 2012, the Company’s shareholders approved a 10 year extension to the Plan, according to which the Board of Directors may grant options under the Plan through May 31, 2023. In December 2017, the shareholders approved an increase of the pool of shares reserved for issuances under the Plan, to 500,000 Ordinary Shares. In July 18, 2018, the Company’s shareholders approved (i) an increase of the number of Ordinary Shares available for issuance under the Plan, by 200,000 to a total of 700,000 Ordinary Shares, and (ii) an amendment of the Plan allowing for the grant of Ordinary Shares in addition to options. Under the Plan, the terms and conditions of the options and the number of shares subject thereto shall be determined by the Board of Directors. The Board of Directors also has discretion to determine the nature of the consideration to be paid upon the exercise of an option under the Plan. Such consideration generally may consist of cash, or, at the discretion of the Board of Directors, cash and a recourse promissory note. The Ordinary Shares acquired upon exercise of an option are subject to certain restrictions on transfer, sale or hypothecation. Options are exercisable and restrictions on disposition of shares lapse pursuant to the terms of the individual agreements under which such options were granted or shares issued. The Company has elected to designate the Plan under the “capital gains” track of Section 102 of Israeli Income Tax Ordinance 5721-1961 (the “Tax Ordinance”), designed to afford qualified optionees certain tax benefits under the Tax Ordinance (a “Section 102 Plan”). Pursuant to the election made by the Company, capital gains derived by optionees arising from the sale of shares pursuant to the exercise of options granted to them under the Plan, will be subject to a flat capital gains tax rate of 25% (instead of the gains being taxed as salary income at the employee’s marginal tax rate). However, as a result of this election, the Company is not allowed to claim the amounts credited to such employees as a benefit when the related capital gains tax is payable by them, as an expense for tax purposes. The Company may change its election from time to time, as permitted by the Tax Ordinance. There are various conditions that must be met in order to qualify for these benefits, including the registration of the options in the name of a trustee (the “Trustee”) for each of the employees who is granted options. Each option, and any Ordinary Shares acquired upon the exercise of the option, must be held by the Trustee for a period commencing on the date of grant and ending no earlier than 24 months from the date of grant. As of December 31, 2020 there are 222,472 options available for future grants under the Plan. Each option granted under the Plan expires five years from the date of the grant. The options vest gradually over a period of up to three years. A summary of the Company’s employee and director stock option activity and related information for the year ended December 31, 2020, is as follows:
|  | 2020 |  |  | 2019 |  |  | 2018 |
|  | Number of options |  |  | Weighted- average exercise price |  |  | Number of options |  |  | Weighted average exercise price |  |  | Number of options |  |  | Weighted- average exercise price |
Outstanding - beginning of year |  |  | 246,874 |  |  | $ | 2.26 |  |  |  | 320,875 |  |  | $ | 2.59 |  |  |  | 314,125 |  |  | $ | 3.39 |
Changes during the year: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Granted |  |  | 45,000 |  |  | $ | 2.55 |  |  |  | 95,000 |  |  | $ | 2.13 |  |  |  | 108,000 |  |  | $ | 2.39 |
Exercised |  |  | (84,618 | ) |  | $ | 2.29 |  |  |  | (125,195 | ) |  | $ | 2.52 |  |  |  | - |  |  | $ | - |
Forfeited |  |  | (36,756 | ) |  | $ | 2.38 |  |  |  | (43,806 | ) |  | $ | 3.65 |  |  |  | (101,250 | ) |  | $ | 4.85 |
Outstanding - year end |  |  | 170,500 |  |  | $ | 2.30 |  |  |  | 246,874 |  |  | $ | 2.26 |  |  |  | 320,875 |  |  | $ | 2.59 |
Vested and expected to vest |  |  | 95,834 |  |  | $ | 2.23 |  |  |  | 148,498 |  |  | $ | 2.41 |  |  |  | 167,874 |  |  | $ | 2.90 |
Exercisable at year end |  |  | 48,834 |  |  | $ | 2.26 |  |  |  | 79,372 |  |  | $ | 2.38 |  |  |  | 157,874 |  |  | $ | 2.89 |
During the years 2020, 2019, and 2018, stock-based compensation expense related to employees and directors stock options amounted to $65, $81 and $67, respectively, and is included in general and administrative expenses within the statement of operations. The weighted-average grant-date fair value of options granted during the years ended December 31, 2020, 2019 and 2018 was $2.31, $1.97 and $ 2.58, respectively. The weighted-average grant-date fair value of unvested options as of December 31, 2020 was $2.86. The aggregate intrinsic value of the outstanding options in each of the years ended December 31, 2020, 2019 and 2018 is $ 0. The aggregate intrinsic value represents the total intrinsic value (the difference between the fair market value of the Company’s Ordinary Shares on December 31 of the respective year and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on such date. During the years ended December 31, 2020 and 2019, exercised options amounted to a total of 84,618 and 125,195, respectively. No options were exercised during the year ended on December 31, 2018. As of December 31, 2020 and 2019, there were a total of $85 and $155, respectively, of unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Company’s Plan. That cost is expected to be recognized through 2022. Options granted to employees and directors that are outstanding as of December 31, 2020 broken into exercise prices, are as follows:
|  |  |  |  |  |  |  |  |  |  | Weighted average |
|  | Options |  |  | Weighted |  |  | Options |  |  | Remaining |
|  | outstanding |  |  | average |  |  | exercisable |  |  | Contractual |
|  | as of |  |  | remaining |  |  | as of |  |  | life of options |
Exercise |  | December 31, |  |  | contractual |  |  | December 31, |  |  | exercisable |
Price |  | 2020 |  |  | life (years) |  |  | 2020 |  |  | (years) |
2.118 |  |  | 74,166 |  |  |  | 3.83 |  |  |  | 15,834 |  |  |  | 3.83 |
2.131 |  |  | 7,167 |  |  |  | 1.93 |  |  |  | 7,167 |  |  |  | 1.93 |
2.176 |  |  | 10,000 |  |  |  | 4.08 |  |  |  | - |  |  |  | 4.08 |
2.287 |  |  | 2,500 |  |  |  | 3.07 |  |  |  | 2,500 |  |  |  | 3.07 |
2.388 |  |  | 41,667 |  |  |  | 2.54 |  |  |  | 23,333 |  |  |  | 2.54 |
2.494 |  |  | 15,000 |  |  |  | 4.75 |  |  |  | - |  |  |  | 4.75 |
2.775 |  |  | 20,000 |  |  |  | 4.96 |  |  |  | - |  |  |  | 4.96 |
Grand Total |  |  | 170,500 |  |  |  | 3.65 |  |  |  | 48,834 |  |  |  | 2.90 |
See also Note 2r regarding the assumptions utilized for the measurement of the fair value of stock options at the grant date.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration